葛蘭素史克(GSK.US)旗下RSV疫苗銷售理想 上調其銷售目標15%
葛蘭素史克(GSK.US)在新呼吸道合胞病毒(RSV)疫苗推出大受歡迎後,周三上調了其長期銷售預測
新疫苗上市僅約半年,銷售額達到約12億英鎊(15億美元)。葛蘭素史克11月時預計該疫苗「Arexvy」於2023年的銷售額將在9億至10億英鎊之間。
葛蘭素史克表示,目前預計到2031年銷售額將超過380億英鎊,高於先前預測的330億英鎊。葛蘭素史克去年收入達303億英鎊;目前預計2021年至2026年間,銷售額複合年增長率將為7%以上,調整後的營業利潤在此期間將增長11%以上。2021年,其指引收入增長率超過5%,盈利增長率超過10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.